Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Paris, France, June 14, 2022 – Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke.
We are excited to today announce the 42 promising start-ups that will go through to the semifinals of EIT Health Catapult 2022-23. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to leading experts and investors. Many participants of the competition have gone on to excel in their respective fields.
We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!
Paris, May 16, 2022 – PKvitality, a French company specializing in Bio-wearable Health and Sports, has been selected to join the 1st promotion of Future4care, the largest eHealth accelerator in Europe.
Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.
The European Stroke Organisation (ESO) is a pan-European society of stroke researchers and physicians, national and regional stroke societies and lay organisations that was founded in December 2007. The ESO is an NGO comprised of individual and organisational members.
Digital Health Innovation: Affidea Signs Partnership With Incepto To Integrate Multi-AI Solutions
Affidea, the largest European provider of advanced diagnostics, outpatient and cancer care services announces a strategic partnership with Incepto, supplier and creator of artificial intelligence solutions in the medical, sector.
|LATTICE MEDICAL DEMARRE SES ESSAIS CLINIQUES 🚀|
Et voilà nous y sommes ! Après 3 ans de travail, nous annonçons le démarrage de nos essais cliniques et l’inclusion d’une première patiente éligible à la reconstruction mammaire avec #MATTISSE dans le cadre de son cancer du sein.
French medtech companies are tackling diabetes and innovating, as proven by the sheer number of patents filed in 2021. Each year, the National Industrial Property Institute (INPI)ranks the top patent filers, highlighting companies that invest in innovation.
Latest Insights
Bouriser.com – Depuis vendredi, l’offre de titres Acticor est lancée dans le cadre de son augmentation de capital d’environ 20
– SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension
Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.
PARIS–(BUSINESS WIRE)–Cibiltech announced today that the first patient has been enrolled in the CIBIL clinical trial “Clinical Impact of the iBox as an early Intervention tool”. A prospective randomized controlled trial to assess the use of a software predicting allograft survival in the follow-up of kidney transplanted patients (NCT05112315). This marks the beginning of this first-of-its-kind clinical trial conducted in Europe evaluating a digital health solution.
One year after its launch in Spain, Vik Asthma received the #EnnovaHealth21 prize by Diario Médico and Correo Farmacéutico in the category #PatientEmpowerment. As our teams continue to grow, we are proud to see the impact that #Vik Asthma has had in patients’ lives, providing support and real-time answers. This couldn’t have been possible without the institutional support of AstraZeneca and local association Fenaer Pacientes.